COVID Articles
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.
Two recent studies effectively determined the antibody responses of pregnant women infected with SARS-CoV-2 and the effect of the fetal sex on those responses, as well as the direct clinical implications for COVID-19 infection and future maternal-fetal vaccination strategies.
The Centers for Medicare & Medicaid Services (CMS) is making it easier to check COVID-19 vaccination rates for nursing home staff and residents by making vaccination data available in a user-friendly format.
The U.S. Department of Health and Human Services (HHS) is making $25.5 billion in new funding available for healthcare providers affected by the COVID- 19 pandemic.
The U.S. Department of Health and Human Services’ Office for Civil Rights (OCR) issued guidance to help the public understand when the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule applies to disclosures and requests for information about whether a person has received a COVID-19 vaccine.
University of Toledo investigators conducted a systematic review and meta-analysis to determine whether there may be an association between hypoalbuminemia and severe COVID-19.
At the end of July, the U.S. Department of Health and Human Services extended the national public health emergency declared for the COVID-19 pandemic, which grants COVID-19 payment and regulatory flexibilities, for another 90 days.
BioRender, an online tool for creating scientific figures, has created a robust, interactive COVID VacTracker that is maintained regularly and updated daily.
The CoVIg-19 Plasma Alliance now includes 11 plasma companies, and now also includes global organizations from outside the plasma industry.
Because research has shown the Bacillus Calmette-Guérin (BCG) tuberculosis vaccine boosts production of immune cells, it is currently being trialed in people as potential protection against COVID-19.
Octapharma USA is supporting a new investigator-initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, Calif., focused on treating the most critical coronavirus patients who are experiencing respiratory failure who become ventilator dependent.
Novartis has initiated a Phase III clinical trial to examine the efficacy of utilizing canakinumab (Ilaris), an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.
